Phase II study of erlotinib in recurrent GBM: Molecular predictors of outcome

1507 Background: Erlotinib (Tarceva) is an orally active, highly potent and selective inhibitor of the epidermal growth factor receptor (EGFR). Preliminary results from this phase II trial of erlot...